FACS FAANS - Aion Therapeutic Medical Director
| ANTCF Stock | USD 0.01 0 84.21% |
Insider
FACS FAANS is Medical Director of Aion Therapeutic
| Phone | 416 460 3000 |
| Web | https://www.aiontherapeutic.com |
Aion Therapeutic Management Efficiency
The company has return on total asset (ROA) of (0.9607) % which means that it has lost $0.9607 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (4.1726) %, meaning that it generated substantial loss on money invested by shareholders. Aion Therapeutic's management efficiency ratios could be used to measure how well Aion Therapeutic manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Elizabeth JD | ANI Pharmaceuticals | N/A | |
| BComm BCom | Akanda Corp | 68 | |
| OriMoni Mimon | INC Research Holdings | 36 | |
| Scott Sudduth | Collegium Pharmaceutical | N/A | |
| Hermann Lubbert | Biofrontera | 68 | |
| Advocate Ohayon | INC Research Holdings | 35 | |
| Erica CPA | Biofrontera | 39 | |
| Rami Levy | INC Research Holdings | 59 | |
| John Weston | cbdMD Inc | N/A | |
| Mark Baldyga | Biofrontera | N/A | |
| Richard MD | Collegium Pharmaceutical | 64 | |
| Eugene III | Biofrontera | 39 | |
| CCFP DipSportMed | Evolus Inc | 60 | |
| Thomas Flow | Akanda Corp | 46 | |
| Alex Dasalla | Collegium Pharmaceutical | N/A | |
| Jeff Holm | Biofrontera | N/A | |
| Matthew Coapman | cbdMD Inc | 48 | |
| Sandra Beaver | Evolus Inc | 46 | |
| Amos Cohen | INC Research Holdings | 45 | |
| Muthusamy RPh | ANI Pharmaceuticals | 56 | |
| Marlo Manning | Collegium Pharmaceutical | N/A | |
Management Performance
| Return On Equity | -4.17 | |||
| Return On Asset | -0.96 |
Aion Therapeutic Leadership Team
Elected by the shareholders, the Aion Therapeutic's board of directors comprises two types of representatives: Aion Therapeutic inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Aion. The board's role is to monitor Aion Therapeutic's management team and ensure that shareholders' interests are well served. Aion Therapeutic's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Aion Therapeutic's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Patricia Purdy, Co Sec | ||
| Graham Simmonds, COO CEO | ||
| FACS FAANS, Medical Director | ||
| Paul Burke, Pres Pharmaceuticals |
Aion Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Aion Therapeutic a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -4.17 | |||
| Return On Asset | -0.96 | |||
| Current Valuation | 1.22 M | |||
| Shares Outstanding | 147.3 M | |||
| Shares Owned By Insiders | 17.68 % | |||
| Price To Book | 5.77 X | |||
| Gross Profit | (1.5 K) | |||
| EBITDA | (3.68 M) | |||
| Net Income | (3.82 M) | |||
| Cash And Equivalents | 1.85 K |
Currently Active Assets on Macroaxis
Other Information on Investing in Aion Pink Sheet
Aion Therapeutic financial ratios help investors to determine whether Aion Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Aion with respect to the benefits of owning Aion Therapeutic security.